TD Waterhouse Canada Inc. Sells 43,830 Shares of AptarGroup, Inc. $ATR

TD Waterhouse Canada Inc. cut its stake in shares of AptarGroup, Inc. (NYSE:ATR) by 96.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,470 shares of the industrial products company’s stock after selling 43,830 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in AptarGroup were worth $184,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of AptarGroup by 28.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,399 shares of the industrial products company’s stock valued at $356,000 after purchasing an additional 534 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of AptarGroup by 22.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 88,716 shares of the industrial products company’s stock valued at $13,164,000 after buying an additional 16,145 shares during the period. Empowered Funds LLC increased its position in AptarGroup by 31.0% in the 1st quarter. Empowered Funds LLC now owns 2,835 shares of the industrial products company’s stock valued at $421,000 after buying an additional 671 shares in the last quarter. Cetera Investment Advisers raised its stake in AptarGroup by 29.3% during the 2nd quarter. Cetera Investment Advisers now owns 3,402 shares of the industrial products company’s stock worth $532,000 after buying an additional 770 shares during the period. Finally, Northwestern Mutual Wealth Management Co. boosted its holdings in AptarGroup by 135.6% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 747 shares of the industrial products company’s stock worth $117,000 after acquiring an additional 430 shares in the last quarter. 88.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Stephan Tanda sold 9,838 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $136.16, for a total value of $1,339,542.08. Following the completion of the sale, the chief executive officer directly owned 238,729 shares of the company’s stock, valued at approximately $32,505,340.64. This represents a 3.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Shiela Vinczeller sold 765 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $130.37, for a total value of $99,733.05. Following the transaction, the insider owned 26,313 shares in the company, valued at approximately $3,430,425.81. This trade represents a 2.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 23,197 shares of company stock worth $3,134,828. 0.73% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have commented on ATR shares. Weiss Ratings reissued a “hold (c)” rating on shares of AptarGroup in a research note on Wednesday, June 24th. Bank of America upgraded AptarGroup from a “neutral” rating to a “buy” rating and set a $173.00 target price on the stock in a report on Tuesday, July 14th. Wells Fargo & Company lifted their price target on shares of AptarGroup from $145.00 to $155.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Finally, Raymond James Financial restated an “outperform” rating and set a $160.00 price target on shares of AptarGroup in a research note on Wednesday, July 15th. Five research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $172.80.

AptarGroup Price Performance

Shares of NYSE ATR opened at $125.00 on Friday. The stock has a market cap of $7.95 billion, a price-to-earnings ratio of 22.60, a PEG ratio of 3.14 and a beta of 0.38. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.10 and a current ratio of 1.61. AptarGroup, Inc. has a fifty-two week low of $103.23 and a fifty-two week high of $146.91. The firm’s 50-day simple moving average is $131.07 and its 200 day simple moving average is $126.87.

AptarGroup (NYSE:ATR) last issued its quarterly earnings data on Thursday, July 30th. The industrial products company reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.35 by $0.07. The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.01 billion. AptarGroup had a return on equity of 13.31% and a net margin of 9.22%.The company’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.66 EPS. AptarGroup has set its Q3 2026 guidance at 1.450-1.530 EPS. As a group, research analysts anticipate that AptarGroup, Inc. will post 5.48 earnings per share for the current fiscal year.

AptarGroup Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, August 20th. Investors of record on Thursday, July 30th were issued a dividend of $0.48 per share. The ex-dividend date was Thursday, July 30th. This represents a $1.92 annualized dividend and a yield of 1.5%. AptarGroup’s dividend payout ratio is 34.72%.

AptarGroup Profile

AptarGroup, Inc is a global supplier of dispensing, packaging and drug-delivery solutions. The company develops and manufactures pumps, valves, aerosol systems, closures, dispensing devices and other components used to package and deliver products in the pharmaceutical, beauty, personal care, food and beverage markets.

Its pharmaceutical offerings include nasal, respiratory, ophthalmic and dermal drug-delivery systems, as well as components and technologies designed to support the administration of prescription and consumer healthcare products.